Recombinant binding proteins and their use

US11332501B2 · kind B2 · utility

Assignee

• Molecular Partners AG · CH

Inventors

• Talitha Bakker · Birmensdorf, CH
• Michael Tobias Stumpp · Geroldswil, CH
• Hans Kaspar Binz · Beaumont, FR
• Douglas Phillips · Baden, CH
• Ignacio Dolado · Rheinfelden, CH
• Patrik Forrer · Schlieren, CH
• Frieder W. Merz · Mellingen, CH
• Ivo Sonderegger · Urdorf, CH
• Daniel Steiner · Bellinzona, CH
• Maya Gulotti-Georgieva · Adliswil, CH
• Johan Abram Saliba · Lausanne, CH

Key dates

• Filing date: Nov 2, 2018
• Grant date: May 17, 2022
• Expiry date: Oct 3, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/62
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (HGF), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (VEGF-A), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.